Topical timolol 0.5% gel-forming solution for erythema in rosacea: A quantitative, split-face, randomized, and rater-masked pilot clinical trial
J Am Acad Dermatol
.
2021 Oct;85(4):1044-1046.
doi: 10.1016/j.jaad.2021.01.098.
Epub 2021 Feb 3.
Authors
Jerry Tsai
1
,
Anna L Chien
1
,
Noori Kim
1
,
Saleh Rachidi
1
,
Brian M Connolly
1
,
Hester Lim
1
,
Sabrina Sisto Alessi César
1
,
Sewon Kang
1
,
Luis A Garza
2
Affiliations
1
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
2
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: LAG@jhmi.edu.
PMID:
33548303
PMCID:
PMC8329126
DOI:
10.1016/j.jaad.2021.01.098
No abstract available
Publication types
Letter
Randomized Controlled Trial
MeSH terms
Double-Blind Method
Erythema / drug therapy
Gels
Humans
Research Design
Rosacea* / drug therapy
Timolol*
Treatment Outcome
Substances
Gels
Timolol
Grants and funding
R01 AR074846/AR/NIAMS NIH HHS/United States